The State of Next Generation Sequencing, in a Glimpse

The State of Next Generation Sequencing, in a Glimpse

A look into the state of things NGS-related with a brief selection of the industry's major players. Plus, an announcement regarding the AACC's 2018 meeting in Chicago.


5 Facts About the Next-Generation Sequencing Market in 2018

5 Facts About the Next-Generation Sequencing Market in 2018

From a focus on a consumables, to new sleek benchtop models, to the surpisingly tenacity of old systems, we review the top insights from Kalorama Information's latest report on the industry.


What Clinical Sequencing Needs

What Clinical Sequencing Needs

Despite the advances in NGS technologies, their successful application and translation to clinical diagnostics must overcome various challenges, detailed in this article.


Big Developments in NGS Market: Assay Kits Appear

Big Developments in NGS Market: Assay Kits Appear

Most sequencing tests performed for clinical applications in the U.S. are laboratory developed tests (LDTs), according to Kalorama Information, meaning that the serviced is performed by test manufacturer and results sent to lab clients. But this is changing, and some of those changes have happened in the last three months. Kalorama Information covers sequencing markets in its report, Next-Generation Sequencing Markets.


In Nanapore Sequencing, Progress and Lawsuits

In Nanapore Sequencing, Progress and Lawsuits

Several companies are competing in the market and in the courtroom to market a diagnostic platform from nanopore technology. There are noted limitations such as data quality, but also progress. A review of the ongoing push for next-generation sequencing at the nano level.


Next-Generation Sequencing: On Our Radar

Kalorama continues to track the sequencing market, which had an estimated $3.8 billion in product revenues in 2015. The market opportunity is evidenced by a number of acquisitions, financing rounds, product launches, and approvals, but six events stand out.


CTCs, cfDNA and Tissue Biopsies: A Comparison

CTCs, cfDNA and Tissue Biopsies: A Comparison

Very small traces of DNA, and the development of tools to detect them, could revolutionize cancer diagnostics and resulting treatment. Circulating tumor DNA (ctDNA, a subset of cell-free DNA) and circulating tumor cells (CTCs) are shed by tumors into the blood and other body fluids. Two technologies in particular, next-generation sequencing (NGS) and digital PCR (dPCR), have allowed scientists to overcome the extremely low concentrations of these analytes. This article discusses the developments and compares the various approaches.


Chinese Market Comes to the Fore in Cancer Diagnostics

Chinese Market Comes to the Fore in Cancer Diagnostics

In 2016, China is a clear market development priority for the IVD industry in the areas of cancer screening tests, companion diagnostics, and sequencing-based cancer assays.


Next-Generation Sequencing Trends

Next-Generation Sequencing Trends

2016 was a good year for next-generation sequencing. Robust investment, new product launches, regulatory clarity are among the trends that Kalorama notes development in this year. Also, NGS products in kit form is moving from theory to reality and China has emerged as a major player in NGS.


IBM Watson Health and Quest Diagnostics’ Bid to Advance Clinical Sequencing Informatics

IBM Watson Health and Quest Diagnostics’ Bid to Advance Clinical Sequencing Informatics

With next-generation sequencing (NGS), research scientists and clinicians are provided abundant raw data, but also too often deficient analytics software also known as informatics. Vendor-specific sequencing informatics software has limited access to third-party research discoveries in genomics. Sequencing analytics already in the clinical field may struggle to remain current with quickly evolving understanding of the genomic, epigenomic and transcriptomic underpinnings in cancer.